BenevolentAI
key required what truly differentiates approach precision medicine for more targeted drugs and clinical trials diseases are commonly by symptoms or location in the body we take a different approach their underlying patient molecular mechanisms or pathways and use from the start of our target process we detect subgroups of patients by applying machine learning approaches to mining multimodal patient level data at scale multimodal clinical trial data knowledge graph detection target prediction a patient centric approach to drug discovery pipelines are based on patient level data such as electronic health record data genetic and data identify and responder patients to design faster more effective clinical trials and increase the probability of clinical success genetic pipelines built for scale faster than traditional pipelines using over of genetic data with better experiment cell line and tissue coverage than industry standard phase trials with selection are more likely to succeed | BenevolentAI
Company
Deck Type
Deck date
December 2021
Slide
16 of 42
Related slides by other companies
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Presentation
March 2023
Investor Presentation
May 2023
Other recent decks by BenevolentAI
Investor Presentation
September 2024
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io